Athenex Announces Positive Recommendations from the Drug Safety Monitoring Board to Continue the Oraxol Phase III Program
October 05, 2017
BUFFALO, N.Y., Oct. 05, 2017 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that a planned interim analysis of the Oraxol 001 Phase III Clinical Trial has been conducted and reviewed by an independent Drug Safety Monitoring Board (DSMB). The DSMB unanimously recommended continuation of the study. The DSMB was impressed by the conduct of the study in achieving a good overall response rate. The DSMB was reassured by the expected difference in safety profile between Oraxol and IV paclitaxel. In particular, the adverse event of painful neuropathy was uncommon with Oraxol treatment. The DSMB encouraged the rapid patient recruitment toward the scheduled second interim analysis at 180 patients.
Athenex, Inc. Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis
September 25, 2017
BUFFALO, N.Y., Sept. 25, 2017 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the recruitment of the first patient into one of two Phase III clinical trials of KX-01 ointment for the treatment of actinic keratosis. KX-01, also known as KX2-391, is a novel molecule in Athenex’s portfolio. KX-01 has multiple mechanisms of action, including inhibition of Src kinase and tubulin polymerization. In preclinical studies, the compound has exhibited a broad range of anti-proliferative activity against a variety of cancer cell types as well as keratinocytes.
Athenex IPO on the NASDAQ Stock Market, June 14, 2017
On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square. Learn More
Governor Cuomo Announces Major Expansion of Athenex — Creating 1,400 Jobs in Western New York
Athenex (formerly Kinex) to invest $1.62 billion in drug discovery and advanced manufacturing partnership, creating 900 jobs in Dunkirk and 500 jobs in Buffalo over the next ten years.
State investing $225 million to support the Buffalo Medical Innovation and Commercialization Hub and help create new opportunities for the region.
Governor Andrew M. Cuomo recently announced a major expansion of Athenex that will create 1,400 jobs throughout Western New York. This announcement, made possible by a partnership with the SUNY Polytechnic Institute, includes a major expansion of Athenex’s North American headquarters at the Conventus Building in Buffalo, as well as the creation of a state-of-the-art, 300,000 square foot manufacturing facility in Dunkirk.
Athenex Completes Public/Private Partnership Agreement with Chongqing, China To Construct Two New Pharmaceutical Manufacturing Plants
Athenex recently announced the completion and execution of a definitive agreement with the Banan District in Chongqing, China to construct two separate pharmaceutical manufacturing plants on Banan sites already identified and selected by Athenex management. Under the terms of the agreement, Banan will provide the funding for the land and construction of the manufacturing plants according to Athenex specifications, and Athenex will equip the facilities.